**Natural Compounds Targeting Cancer Stem Cells: A Promising Resource for Chemotherapy**

Plabon K. Das¹,†, Tasnim Zahan¹,†, Md. Abdur Rakib¹, Jahan A. Khanam¹, Suja Pillai² and Farhadul Islam¹,²,*

¹Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi-6205, Bangladesh; ²School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Australia

**Abstract: Background:** Cancer Stem Cells (CSCs) are the subpopulation of cancer cells which are directly involved in drug resistance, metastases to distant organ and cancer recurrence.

**Methods:** A systemic literature search was conducted through various electronic databases including, Pubmed, Scopus, Google scholars using the keywords "cancer stem cells" and "natural compounds" in the present study. Articles published between 1999 and 2019 were reviewed. All the expositions concerning CSCs associated cancer pathogenesis and therapy resistance, as well as targeting these properties of CSCs by natural compounds were selected for the current study.

**Results:** Natural compounds have always been thought as a rich source of biologically active principles, which target aberrantly activated signaling pathways and other modalities of CSCs, while tethering painful side effects commonly involved in the first-line and second-line chemo-radiotherapies. In this review, we have described the key signaling pathways activated in CSCs to maintain their survival and highlighted how natural compounds interrupt these signaling pathways to minimize therapy resistance, pathogenesis and cancer recurrence properties of CSCs, thereby providing useful strategies to treat cancer or aid in cancer therapy improvement. Like normal stem cells, CSCs rely on different signaling pathways and other properties for their maintenance. Therefore, the success of cancer treatment depends on the development of proper anti-neoplastic drugs capable of intercepting those signaling pathways as well as other properties of CSCs in order to eradicate this evasive subpopulation of cancer cells.

**Conclusion:** Compounds of natural origin might act as an outstanding source to design novel therapies against cancer stem cells.

**Keywords:** Natural compounds, cancer stem cells, signaling pathways, cancer therapy, therapy resistance, pathogenesis.

**1. INTRODUCTION**

Cancer is a group of diseases that develop due to the accumulation of genetic and epigenetic alterations. These changes make one cell or few cells begin to grow and multiply indefinitely without control, resulting in an abnormal growth called tumor or neoplasm [1]. Despite the advancement in understanding the molecular basis, diagnosis and treatment of cancer, long-term survival rates of patients with cancer have to be achieved [2, 3]. Resistance to the first line and second line chemo-radiotherapies and cancer recurrence contributed to the limited overall survival of patients with various types of cancer [4].

Emerging evidence suggested that a subpopulation of cancer cells known as Cancer Stem Cells (CSCs) are responsible for tumor initiation, therapy resistance, metastasis and recurrence [5-7]. In addition, these CSCs exhibit greater tumorigenic and metastatic potential than non-CSCs, *i.e.* bulk cancer cells [8]. Conventional first line and second line chemotherapy regimen(s) target bulk of tumor cells, thereby CSCs escaping these therapeutics due to their high resistance and can effectively repopulate a tumor [2]. Multiple factors, including, escaping apoptotic insults, overactivation of drug-efflux pumps, increased DNA repair capacity, activation of detoxification enzyme and undergoing a quiescent state of CSCs attributed to the pro-survival mechanisms of CSCs, resulting in therapy resistance [9]. Moreover, several signaling pathways such as Wnt/β-catenin, Hedgehog, and Notch signaling are highly active in many CSCs, thereby contributing to therapy resistance and cancer recurrence [10]. For example, activation of Wnt/β-catenin promotes sphere formation, differentiation ability, self-renewal and tumor developmental cell fate in various cancer [10-12]. Activation of Notch signaling regulates morphogenesis and stem cell maintenance, whereas activation of Hedgehog signaling promotes expansion, proliferation, and self-renewal of stem cells [13]. Thus the development of therapeutics targeting these signaling pathways’ component and/or mechanism attributed to drug resistance of CSCs, could have the potential to prevent drugs resistance and cancer recurrence [14, 15]. Furthermore, side effects of conventional therapy limit their applications in clinical settings. For example, current chemotherapies such as using monoclonal antibodies, tyrosine kinase inhibitors and other targeted therapies have been associated with cardiovascular side-effects, including cardiomyopathy and congestive heart failure [16, 17]. Some of these agents are even involved with an increased risk of coronary artery disease with or without myocardial infarction [16]. However, nutraceuticals or compounds of natural origin, are beneficial to vascular health and impose less or no cardiovascular side effects [17]. Therefore, taking
into account the less or no side effects and universal availability, researchers have shifted their focus on compounds of natural origin to identify novel therapeutics targeting CSCs [18]. Biologically active principles of natural origin have pharmacological applications against different types of diseases, including cancers [19]. Consequently, to deal with the difficulties of treating CSCs, natural compounds may be a potential resource to discover novel therapeutic options. Interestingly, the roles of natural compounds on a diminished activity of multiple signaling pathways and minor side effects have led researchers to investigate their effect on CSCs [19]. Natural compounds e.g. curcumin [20], quercetin and epigallocatechin gallate target the self-renewal pathways of CSCs, thereby providing a potential strategy to eradicate CSCs, resulting in nullifying tumor resistance and cancer relapse [21, 22]. Herein, in this review, we discuss the roles of the CSCs in tumorigenesis and therapy resistance along with the promising roles of natural compounds targeting CSCs. In addition, the mechanisms by which natural products exhibited their anti-CSCs activity have been presented.

2. CANCER STEM CELLS (CSCS)

Cancer Stem Cells (CSCs) are very similar to normal stem cells, especially with their ability to give rise to all cell types in a particular cancer [23]. In addition, CSCs share several properties with normal stem cells, including membrane transport, DNA repair, ability to regulate self-renewal and differentiation in response to oncogenic mutations and external stimulations [24]. However, they exhibit some distinct features e.g. spheroid formation in culture, expression of specific marker proteins (aldehyde dehydrogenase; ALDH, cluster of differentiation 133; CD133, cluster of differentiation 44; CD 44 etc), expression of multi-drug resistance proteins and anti-apoptotic proteins [25-28]. This subpopulation of cells may arise from normal stem cells or progenitor cells, adipose-derived stromal cells or even from differentiated cells through dedifferentiation [29]. CSCs are found in hematological cancers and in many solid tumors, including melanoma, osteosarcoma, prostate, ovarian, gastric, glioblastoma and their tumorigenic capability is highly influenced by tumor microenvironment [30, 31]. Furthermore, heterogeneity is another vital characteristic of CSCs that added more difficulties in designing therapy against these distinct phenotypes of tumour population [32]. Additionally, plasticity provides a dynamic ability, through which cells can switch from a non-CSC state to a CSC state and vice versa. Cancer cells gain this ability through specific microenvironmental signals and cellular interactions arising from the tumor niche [32].

2.1. CSCs in Cancer Pathogenesis

It is evident that CSCs play critical roles in all stages of tumorigenesis namely initiation, progression, invasion, metastasis, therapy resistance and recurrence [33, 34]. They guide metastasis through the Epithelial-Mesenchymal Transition (EMT) process [35]. Evidently, early metastatic cells that disseminated in the lungs exhibited stemness markers in mice model [36]. In addition, CSCs support angiogenesis via promoting the expression of angiogenic factors i.e. Epidermal Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF) etc, which stimulate new blood vessel formation [37]. Moreover, CSCs show vasculoangiogenic mimicry activity [38]. Furthermore, aberrant activation of signaling pathways in CSCs has been involved in the manifestation of the pathophysiology of tumorigenesis [39].

2.2. CSCs in Therapy Resistance

The main challenge in current cancer treatment is therapy resistance, thereby cancer recurrence. This therapy resistance is contributed by CSC via multiple ways i.e. enhanced DNA repair efficiency, detoxification enzyme expression (ALDH), mutations in key signaling molecules, increased expression of drug resistance proteins, up-regulation of anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, Bcl-w) and overexpression of drug efflux pumps [27, 40-42]. For instance, CD133+ glioma CSCs have been reported to be resistant to radiation therapy [41, 42]. Additionally, activation of oncoproteins associated with the maintenance of stemness and tumorigenicity of CSCs [43, 44]. For example, RAD51, a recombination, involved in DNA repair, is overexpressed in a treatment-resistant variety of tumors including ovarian, prostate, colorectal cancer and malignant gliomas [45, 46]. Moreover, CSCs showed up-regulation of several ATP-binding cassette (ABC) transporters family proteins (ABCG2, ABCB1, and CEACAM6) which efflux chemotherapeutic drugs efficiently [47]. Therefore, the molecular underlyingle CSCs therapy resistance opens up a new horizon for developing new drugs to treat cancer more effectively.

3. NATURAL COMPOUNDS TARGETING CANCER STEM CELLS

Traditional cancer therapies like chemotherapy and radiation therapy fail to target cancer stem cells and furthermore, non-specificity of these therapies causes toxicity to normal cells [15]. Interestingly, many natural compounds have already demonstrated anti-CSCs properties both in vivo and in vitro [19]. These findings suggested that natural compounds may have the potential to induce death of CSC. Besides that, natural compounds could make them sensitized to conventional therapies, forcing them to re-differentiate or preventing them from entering a dormant or resistant state, thereby having the potential of improving cancer management in clinical settings [19]. In the following sections, the roles of natural compounds against CSCs in various cancers are described.

3.1. Natural Compounds Targeting Signaling Pathways in CSCs

There are several signaling pathways such as Wnt/β-catenin, Notch, Hedgehog signaling overactivated in CSCs. Diverse alterations in these signaling pathways accumulated in CSCs and contributed to cancer initiation, progression, and recurrence [15]. Natural compounds exhibit anti-CSCs activity by interrupting different signaling pathways or their components are summarized in Table 1.

3.2. Natural Compounds Targeting the Wnt/β-Catenin Signaling Pathway

Wnt/β-catenin signaling is strongly associated with tumor formation in different types of cancer [11]. This pathway is a key player in the initiation and progression as the elevated levels of β-catenin could direct the cell fate [48, 49]. Tumorigenic properties of CSCs such as sphere formation, differentiation, and in vivo tumor development abilities of CSCs are regulated by Wnt/β-catenin signaling [50]. Natural compounds such as Epigallocatechin-3-Gallate (EGCG), Diallyl trisulphide (DATS), Chinese Bayberry Leaf Proanthocyanidins (BLP), Ginsenoside Rb1, Sulforaphane and Isoliquiritigenin have the potential to interact with the elements of Wnt/β-catenin signaling, resulting in inhibition of CSCs growth and development (Fig. 1) [50-56]. For example, Epigallocatechin-3-Gallate (EGCG) has been isolated from green tea (Camellia sinensis), interacts with Wnt/β-catenin signaling component GSK3β in DLD-1 and SW480 colon cancer cell lines, thereby inhibiting their growth and proliferation. Treatment of colon cancer cells with EGCG downregulates the expression of p-GSK3β (inactivated) and up-regulates the expression of GSK3β (activated), consequently decreasing the level of β-catenin and its target gene c-myc, resulting in reduced cell growth and proliferation (Fig. 1) [50]. Though, in vivo anti-CSCs activity of EGCG in colon cancer has not been evaluated yet, accumulating evidence has shown that EGCG exhibits its anti-cancer properties in various types of cancers, including bladder cancer [57], melanoma [58] and lung cancer [59]. It exhibit-
Table 1. Different natural compounds target different pathways in various cancer types.

<table>
<thead>
<tr>
<th>Natural Compounds</th>
<th>Source</th>
<th>Target Pathway(s)</th>
<th>CSCs in Cancer Types</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG</td>
<td>Camellia sinensis</td>
<td>Wnt/β-catenin</td>
<td>Colon</td>
<td>[50]</td>
</tr>
<tr>
<td>DATS</td>
<td>Allium sativum</td>
<td>Wnt/β-catenin</td>
<td>Colon</td>
<td>[51]</td>
</tr>
<tr>
<td>BLP</td>
<td>Morella rubra</td>
<td>Wnt/β-catenin</td>
<td>Ovarian</td>
<td>[52]</td>
</tr>
<tr>
<td>Compound k</td>
<td>Panax quinquefolia</td>
<td>Wnt/β-catenin</td>
<td>Ovarian</td>
<td>[53]</td>
</tr>
<tr>
<td>Isoliquiritigenin</td>
<td>Glycyrrhizaglabra</td>
<td>Wnt/β-catenin</td>
<td>Breast</td>
<td>[55, 56]</td>
</tr>
<tr>
<td>Sulforaphane</td>
<td>Brassica oleracea var.</td>
<td>Wnt/β-catenin, Notch, Hedgehog</td>
<td>Breast, Pancreatic</td>
<td>[55, 56]</td>
</tr>
<tr>
<td>Alpinetin</td>
<td>Alpinia zerumbet</td>
<td>Notch</td>
<td>Glioblastoma</td>
<td>[66]</td>
</tr>
<tr>
<td>Eckol</td>
<td>Eclkonria cava</td>
<td>Notch, PI3K-Akt and Ras-Raf-1-Erk.</td>
<td>Glioblastoma</td>
<td>[67]</td>
</tr>
<tr>
<td>Genistein</td>
<td>Glycine max</td>
<td>Hedgehog</td>
<td>Breast</td>
<td>[75]</td>
</tr>
<tr>
<td>Homokiol</td>
<td>Magnolia officinalis</td>
<td>Notch</td>
<td>Melanoma</td>
<td>[69]</td>
</tr>
<tr>
<td>Cyclopamine</td>
<td>Veratum californicum</td>
<td>Hedgehog</td>
<td>Leukemia</td>
<td>[72]</td>
</tr>
<tr>
<td>Nitidine chloride</td>
<td>Zanthoxylum nitidum</td>
<td>Hedgehog</td>
<td>Breast</td>
<td>[73]</td>
</tr>
<tr>
<td>Hinokitiol</td>
<td>Chamaecyparis taiwanesisis</td>
<td>Nrf2</td>
<td>Glioblastoma</td>
<td>[76]</td>
</tr>
<tr>
<td>Plumbagin</td>
<td>Plumbago zeylanica</td>
<td>Nrf2</td>
<td>Squamous carcinoma</td>
<td>[84]</td>
</tr>
<tr>
<td>Triptolide</td>
<td>Tripterygium wilfordii</td>
<td>Nrf2</td>
<td>Leukemia</td>
<td>[85]</td>
</tr>
<tr>
<td>BBMD3, synthetic derivative of Berberbine</td>
<td>Berberis amurensis</td>
<td>JNK/AP-1</td>
<td>Glioblastoma, Osteosarcoma</td>
<td>[86-87]</td>
</tr>
<tr>
<td>Compound 2</td>
<td>Garcinia hanburyi, Garcinia Morella</td>
<td>Akt/Erk</td>
<td>Head and neck</td>
<td>[88]</td>
</tr>
<tr>
<td>BMR270 (extract)</td>
<td>Medicinal Plants</td>
<td>NF-κβ</td>
<td>Osteosarcoma</td>
<td>[78]</td>
</tr>
<tr>
<td>Nutraecuticals</td>
<td>Medicinal Plants</td>
<td>-</td>
<td>-</td>
<td>[17]</td>
</tr>
</tbody>
</table>

Note- EGCG: Epigallocatechin-3-Gallate; DATS: diallyl trisulphide; BLP: Bayberry leaf proanthocyanidins; PI3K: Phosphatidylinositol 3-kinase; Akt: Protein kinase B; Raf: Rapidly Accelerated Fibrosarcoma; Nrf2: NF-E2-related factor 2, JNK: c-Jun NH2-terminal kinase (JNK); AP-1: Activator protein-1; Erk: Extracellular-regulated kinase; NF-κβ: Nuclear factor kappa β.

Sulforaphane, a dietary compound isolated from broccoli (Brassica oleracea var.) downregulates Wnt/β-catenin pathway in human breast cancer cells [54]. This compound decreased the expression of β-catenin up to 85% as well as decreased the expression of cyclin D1 by 77% in MCF-7 and SUM159 cell lines. Furthermore, in vivo activity of sulforaphane was also determined in breast cancer cells injected immunocompromised NOD/SCID mice. Daily injection of sulphoraphane for two weeks decreased tumor growth in primary NOD/SCID mice and reduced ALDH-positive cell population of the tumors by ~50%. More importantly, they found that the tumor cells derived from sulforaphane-treated mice were not able to form secondary tumors in recipient mice up to 33 days of implantation [54]. However, sulforaphane could act as a double-edged sword. On the one hand, it reduces carcinogenesis; on the other hand, it blocks the T cell-mediated immune response which is important for immune surveillance of tumors [62]. Sulforaphane inhibits T cell activation and T cell effector functions by increasing intracellular ROS levels and decreasing GSH [62]. Thus, it could interfere with the successful application of immunotherapy by immune checkpoint inhibitors (e.g. CTLA-4 antibodies and PD-1/PD-L1 antibodies) or chimeric antigen receptor (CAR) T cells [62]. All these setbacks should be considered before applying sulforaphane in human.

Another natural compound BLP, isolated from Chinese bayberry (Morella rubra) leaf, targets Wnt/β-catenin signaling and induces degradation of β-catenin in ovarian cancer cells [52]. BLP stimulates degradation of β-catenin in a dose-dependent manner by up-regulation of p-GSK3β and reduction of non-phosphorylated GSK3β along with inhibition of Akt activity [52]. Subsequently, the expression of β-catenin downstream targets genes such as cyclin D1 and c-myc was down-regulated, resulting in reduced cell growth and proliferation.

Ginsenoside Rb1, is a natural saponin, isolated from the rhizome of Panax quinquefoliu and its metabolite compound k has the potential to target Wnt/β-catenin signaling, thereby inhibiting CSCs growth and reversing therapy resistance of ovarian cancer cells both in vivo and in vitro [53]. Compound k induced inhibition of ABCG2 and p-glycoprotein expression (two critical drug transporters) by interrupting the binding of β-catenin with T-cell factor (TCF/LEF) (Fig. 1). The binding of β-catenin to TCF/LEF is critical for mediating its downstream function such as transcription of target genes involved in cell growth, division and survival [53]. Thus, treatment of CSCs with compound k inhibits Wnt/β-catenin signaling, resulting in reduced cell growth and proliferation.

Isoliquiritigenin (ISL) isolated from Licorice root exhibited anti-CSCs activity in both MMTV-PyMT mice model and breast cancer cells (MDA-MB-231), by targeting the Wnt/β-catenin signaling pathway via modulating WIF1 expression [55]. Treatment of CSCs with ISL induces down-regulation of both the cytopsolic and nuclear β-catenin expression, indicating that downregulation of β-catenin might occur in post-translational level. Furthermore, a WIFI-antibody was used to examine whether this effect is critical for down-regulation of β-catenin or not. It was noted that inhibition of WIFI reverses the downregulation of β-catenin expression in MDA-MB-231 breast cancer cells followed by ISL treatment. Eventually, the expression of β-catenin was increased significantly with the supplementary WIFI-neutralizing antibody. These results indicate that ISL interacts with the Wnt/β-catenin pathway through modulating WIFI expression [55]. Moreover, inhibition of β-catenin expression resulted in increasing chemosensitivity of cancer.
cells with the treatment of ISL by down-regulation of ABCG2, which is a downstream target gene of β-catenin (Fig. 1). In addition, ISL exhibited synergistic anti-CSC activity when applied with epirubicin (an anticancer drug) via inducing reduced expression of β-catenin and ABCG2 [55]. Inhibition of β-catenin downstream genes including cyclin D1, survivin, Oct-4, c-myc, and ABCG2 in ISL treated cells suggested that β-catenin inhibition might occur at the post-translational level. Furthermore, it was demonstrated that ISL induces proteasomal degradation of β-catenin by interacting Akt/GSK3β pathway [55]. Moreover, using drug affinity responsive target stability strategy, it was further identified that ISL directly targets GRP78. Subsequent molecular docking analysis and functional studies demonstrated that ISL could dock into the ATP domain of GRP78 and thereby inhibit its ATPase activity, resulting in dissociation of GRP78 from β-catenin. Also, an in vivo study suggested that ISL could chemosensitize breast CSCs via the GRP78/β-catenin/ABCG2 pathway, with little toxicity in normal tissues and mammary stem cells [56]. Therefore, anti-CSCs activities of different natural compound provide a new horizon by interrupting aberrant activation of Wnt/β-catenin signaling.

3.3. Natural Compounds Targeting the Notch Signaling Pathway

Notch signaling, an evolutionarily conserved pathway, plays a pivotal role in embryonic development, organ development and the regulation of self-renewal in normal stem cells and subsequently maintains tissue homeostasis [63, 64]. However, in the context of
disrupting signaling pathways, this signaling is intensively activated in CSCs and mediates the critical processes of carcinogenesis, including angiogenesis, EMT and metastatic spread of a tumor [65]. A number of natural compounds such as Alpinetin, Eckol, Sulforaphane, and Honokiol isolated from medicinal and edible plants, exhibited anti-tumor activities by targeting CSCs in many cancer via suppressing Notch singling pathway (Fig. 2) [66-69]. For instance, alpinetin isolated from edible plants such as Alpinia zerumbet, can reduce the invasiveness, proliferation and induce apoptosis in a dose and time-dependent manner in orthopic GSC xenograft model [66]. In GSC, alpinetin induced proteolytic cleavage of Notch protein thereby reducing the expression of Notch target genes i.e. HES and c-Myc [66]. Eckol, another natural compound isolated from brown algae Ecklonia cava showed anti-CSCs activity via reducing the expression of Notch protein in GSC [67].

Additionally, sulforaphane induced down-regulation of Notch-1 expression in pancreatic CSC [68]. Consistently, downregulation of Notch-1 caused inhibition of c-Rel (a transactivation-potent subunit of the NF-kB transcription factor) expression, resulting in inactivation of NF-kB signaling in pancreatic CSC [68]. Thus, sulforaphane could potentially inhibit NF-kB signaling in CSC through Notch-1 downregulation (Fig. 2). Furthermore, a recent study reported that honokiol, a biphenolic compound extracted from Magnolia Officinalis, suppresses the aberrant activation of Notch signaling in mesenchymal stem cells of B16/F-10 and SKMEL-28 melanoma cell lines [69]. Proteolytic cleavage of the Notch receptor is crucial to inactivate Notch signaling and interestingly it was noted that honokiol treatment induced proteolytic degradation of Notch-2 receptor in melanoma CSCs [69]. Subsequently, the expression of downstream targets of Notch signaling such as Hes-1 and cyclin D1 was declined in honokiol treated mesenchymal stem cells, thereby inhibiting growth and proliferation of melanoma stem cells (Fig. 2) [69]. As the Notch signaling pathway is deeply associated with cancer progression, therefore targeting this pathway by these natural compounds may provide a fruitful way to treat cancer.

### 3.4. Natural Compounds Targeting the Hedgehog Signaling Pathway

The Hedgehog pathway mediates the embryonic development of both vertebrates and invertebrates and also contributes to organ and tissue formation including neural tube [70]. As a consequence, like Wnt/β-catenin and Notch signaling, aberrant activation of Hedgehog pathway has also been noted in CSCs, which plays a vital role in multiple steps of tumor progression, including migra-
tion, invasion, and metastasis [71]. Treatment of cancer cells with compounds of natural origin such as Cyclopamine, Nitidine chloride, Sulforaphane, Genistein could potentially kill CSCs by targeting the Hedgehog pathway components, resulting in inactivation of signaling cascade (Fig. 3) [72-75]. For example, cyclopamine is a teratogen isolated from the Veratrum californicum, induced apoptosis in CD34+ AML cancer stem cells [72]. Cyclopamine affects the survival of AML stem cells by modulating G protein-coupled receptor Smo. Moreover, the anti-CSCs effect of cyclopamine was noted to be stem cell-specific as it fails to exhibit growth inhibitions or survival of leukemia cells lacking expression of Hedgehog receptor components [72]. In addition, treatment of drug-resistant CD34+ (resistant to cytarabine) with cyclopamine increased the chemosensitivity of CD34+ cell lines against cytarabine (Fig. 3) [72]. Nitidine Chloride (NC) derived from roots of Zanthoxylum nitidum targets Hh signaling MDA-MB-468 and MCF-7 breast cancer cell lines via inducing downregulation of Hh receptors (Smo, Patched) and activators Gli1, Gli2 [73]. NC in combination with Smo inhibitor cyclopamine exhibited synergistic effect on Gli and CD44 marker downregulation as well as inhibited the migration of breast cancer cells [73].

In addition to the inhibition of Wnt/β-catenin and Notch signaling, Sulforaphane significantly inactivates Hh signaling in pancreatic cancer stem cell [74]. In pancreatic CSCs, hyperactive Sonic Hh signaling is involved in the regulation of stemness genes expression [74]. It was demonstrated that Sulforaphane treatment can target Hedgehog signaling in pancreatic CSCs and reduced the expression of Smo (receptor), Gli1 and Gli2 (effectors). Moreover, sulforaphane treatment can inhibit nuclear translocation of both Gli1 and Gli2 transcriptional effectors in a dose-dependent fashion. Consistently, the downstream targets of Hh signaling especially in pancreatic CSCs, which are involved in proliferation undergo down-regulation, thereby inhibit cell growth and proliferation [74] (Fig. 3).

Another natural isoflavone Genistein of Glycine max inhibits breast cancer stem cells originated from MCF-7 cells via targeting-Hedgehog-Gli1 signaling pathway [75]. Genistein induces reduced expression of Smo and Gli1 at both mRNA and protein level in breast cancer CSCs [75]. Therefore, natural compounds exert their anti-CSCs effect by targeting key signaling pathway components or inducing down-regulation of their targets, resulting in inhibition of cancer cell growth and proliferation. The findings of the of these
studies led us to the hypothesis that these compounds could provide a way to make suitable anticancer drug by targeting key singling pathways or their components in CSCs.

3.5. Natural Compounds Targeting Other Pathways in CSCs

There are some other signaling pathways such as NF-κB-related factor 2 (Nrf2), JNK/AP-1, NF-κB etc which are also implicated in CSCs [76, 78]. Thus, targeting these pathways by naturally occurring compounds is of great importance as well. Nrf2 is thought of as a useful factor that protects human from carcinogenic chemicals [79]. It is a transcription factor that helps chemotherapeutic compound including detoxifying enzyme, antioxidants, and transporters to defend the cells from carcinogenic insults [79]. Moreover, it is evident that Nrf2 plays dual roles in cancer pathogenesis i.e. protects normal cells from transforming into cancer cells, and also nourishes the survival of cancer cells in tumor microenvironment [79]. A growing body of evidence suggests that increased activity of Nrf2 due to NFE2L2 or KEAP1 (Kelch-like ECH associated protein 1) mutations play a significant role in the pathogenesis of many solid tumors [80]. For instance, it has recently emerged as one of the main pathways implicated in renal carcinoma [80]. Moreover, it was also demonstrated that KEAP1-Nrf2 polymorphism also occurred in breast cancer [81]. In addition, Nrf2 promotes metastatic breast cancer cell migration via upregulation of glucose-6-phosphate dehydrogenase (G6PD), Hypoxia-inducing factor 1α (HIF-1α) in MCF-7 and MDA-MB-231 cells [82]. Furthermore, in lung cancer, it was observed that, Keap1-Nrf2 signaling plays a critical role in response to oxidative stress. Mutations in KEAP1/NFE2L2 genes always cause persistent Nrf2 activation in lung cancer cells that confer therapeutic resistance and aggressive tumorigenic activity [83]. Thus, Nrf2 suppression with chemical agents which cause enhanced oxidative imbalance or abnormal metabolism would be promising in the treatment of lung adenocarcinoma. Targeting Nrf2 with natural compounds could induce down-regulation of Nrf2, subsequently inhibiting its tumor promoting activity. It was reported that Nrf2 expression was upregulated in Glioma stem cells [76]. Treatment of these cells with a natural bioactive compound Hinokitiol, isolated from Chamaecyparis taiwanensis induces down-regulation of Nrf2 in Glioma stem cells in a dose-dependent manner. In addition, it inhibited the expression of Nrf2 target genes such as heme oxygenase 1 (HO-1) and glutathione S-transferase, thereby nullifying Nrf2 mediated carcinogenic insults in Glioma stem cells [76]. Plumbagin, a natural naphthoquinone isolated from Plumbago zeylanica, inhibited nuclear translocation of Nrf2, resulting in inactivation of Nrf2-mediated oxidative stress signaling pathway in squamous cell carcinoma cells [84]. It was noted that treatment of squamous cell carcinoma cells with Plumbagin induces reduced proliferation, activated death receptor-mediated apoptosis and inhibited epithelial to mesenchymal transition, thereby reducing CSCs’ properties of squamous cell carcinoma cells [84]. Furthermore, Triptolide, (a bioactive diterpenoid trioxipoxide of Chinese medicinal plant Tripterygium wilfordii) has been found to be effective against Leukemia stem-like cells via downregulation of Nrf2 pathway [85].

The stress-responsive JNK/AP-1 signaling pathway is involved in cell growth, transformation and apoptosis [77]. JNK-1 and JNK-2 are key mediators of this pathway, which cause phosphorylation of c-Jun, a major protein of activator protein-1 complex. Activation of JNK/AP-1 signaling pathway usually induces apoptosis [77]. A bioactive natural compound can activate this pathway via interaction with the components and could induce anti-CSC activity in cancer. For example, Berbamine isolated from Berberis amurensis and its synthetic derivative BBMD3 exhibited anti-cancer effects in glioblastoma-derived cancer stem-like cells through activation of JNK/AP-1 signaling pathway [86]. In addition, BBMD3 inhibited cell viability and induced apoptosis in human osteosarcoma cells via activation of JNK/AP-1 [87].

EGFR, an intrinsic tyrosine kinase, when binds with its ligand EGF, results in autophosphorylation of tyrosine residues on the EGFR and subsequently activating signal transduction pathways that involved in regulating cellular proliferation, differentiation, and survival [88]. Up-regulation of EGFR occurred in head and neck squamous cell carcinoma [88]. Compound 2, a derivative of Chinese medicine called gambosse (prepared from Garcinia hanburyi, Garcinia Morella like plants), exerted dose-dependent inhibitory effect against head and neck squamous cancer stem-like cells in xenograft tumor model via downregulation of EGFR and phosphorylation of Akt and Erk [88].

The transcription factor NF-κB stimulates expression of anti-apoptotic genes. Hence, overexpression of NF-κB induces tumorigenesis in association with Cdk6 and p65 in the stem-like cancer-initiating cells in osteosarcoma-derived cells [78]. Plant extract BMR270 treatment dramatically inactivates NF-κB signaling cascade in MDR-induced stem-like cancer-initiating cells in osteosarcoma derived CSCs [78]. Thus, besides Wnt/b-catenin, Notch, Hedgehog signaling, other pathways like Nrf2, EGFR and NF-κB are also involved in CSCs properties. Therefore, inhibition of these pathways or their components by natural compound may provide a way to treat cancer.

3.6. Natural Compounds Targeting Other Modalities of CSCs Rather Than Signaling Pathways

There are a number of natural compounds that do not directly target signaling pathways or their molecular mechanisms are yet to be discovered (Table 2). In the following sections, we will review those compounds of natural origin that could potentially target CSCs.

MicroRNAs (miRNAs), a class of small noncoding RNAs, regulate the expression of a gene at the post-transcriptional level by binding to target mRNAs within the 3′ untranslated region (UTR) [89]. They have been found to be involved in many important biological processes [89-91]. For example, miR-218 acts as a tumor suppressor by targeting many oncogenes related to proliferation, apoptosis, and invasion [92-94]. A number of studies have shown that miRNA engaged in the regulation of CSCs properties [95-97]. Andrographolide, a bioactive compound isolated from Andrographis paniculata, inhibited cell proliferation and self-renewal of oral cancer stem cells by increasing the expression of miR-218 [95]. MiR-218 induces downregulation of Bmi1, which is a transcription factor associated with self-renewal, tumor cell motility and invasion of Oral Cancer Stem Cells (OCCS) [95]. In addition, Andrographolide supplementation mediated downregulation of Bmi1 through up-regulation of miRNA-218, which subsequently inhibits tumor growth in immunocompromised mice bearing OSCC xenograft [95].

Hinokitiol, also known as β-Thujaapicin, isolated from heartwood Cupressaceae (Cupressus sempervirens, Hinoki cypress), inhibits vasculogenic mimicry activity in breast cancer stem cells by stimulating proteasomal degradation of EGFR [96]. In addition, Hinokitiol inhibited colony formation ability of glioma stem cells and reduced cell viability in a dose-dependent manner [97].

Dietary compound isoliquiritigenin (ISL) reduces colony forming and invasive activities of Oral Squamous Cell Carcinoma Cancer Stem Cells (OSCC-CSC) when administered alone or in combination with cisplatin [98]. ISL treatment in OSCC-CSC induced down-regulation of CD44, ABCG2 and cell surface GRP78 protein expression in OSCC-CSCs [92]. GRP78 is a component of GRP78/Bip/HSPA5 chaperon which anchors in the cell membrane and promotes tumor cell proliferation [99]. Thus, ISL exerts chemosensitizing effects via GRP78 in OSCC-CSCs as GRP78 is the direct target of ISL in inhibiting β-catenin/ABCG2 signaling [98].
Apoptotic activity [102]. In addition, Triptolide exhibits cytotoxic 
2 in a nucleolus compartment, thereby freeing p53 to mediate its 

Table 2. Natural compounds those mediate their function by targeting other features of CSCs rather than signaling pathways.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>Source</th>
<th>Molecular Target (s)</th>
<th>CSCs in Cancer Types</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrographolide</td>
<td>Andrographis paniculata</td>
<td>miRNA-218</td>
<td>Oral</td>
<td>[95]</td>
</tr>
<tr>
<td>Hinokitiol</td>
<td>Cupressus sempervirens, Hinoki cypress</td>
<td>EGFR</td>
<td>Breast, Glioma</td>
<td>[96-97]</td>
</tr>
<tr>
<td>Isoliquiritigenin</td>
<td>Glycyrrhiza glabra</td>
<td>GRP78 protein</td>
<td>Oral squamous cell carcinoma</td>
<td>[98]</td>
</tr>
<tr>
<td>Wogonin</td>
<td>Scutellaria baicalensis</td>
<td>MMP-9</td>
<td>Osteosarcoma</td>
<td>[100]</td>
</tr>
<tr>
<td>Catharanthine</td>
<td>Mylabris, quadrapunctata, Hyaleus lugen</td>
<td>Colony formation</td>
<td>AML</td>
<td>[101]</td>
</tr>
<tr>
<td>Indole carbinol</td>
<td>Brassica genus</td>
<td>Nucleostemin</td>
<td>Breast</td>
<td>[102]</td>
</tr>
<tr>
<td>Triptolide</td>
<td>Tripterygium wilfordii</td>
<td>Apoptotic genes</td>
<td>Breast</td>
<td>[103]</td>
</tr>
<tr>
<td>Shikonin</td>
<td>Lithospermum erythrorhizon</td>
<td>SOX9/miRNA</td>
<td>Breast</td>
<td>[104]</td>
</tr>
<tr>
<td>β-escin</td>
<td>Aesculus hippocastanum</td>
<td>ALDH, SOX2, Nestin</td>
<td>Glioma</td>
<td>[105]</td>
</tr>
<tr>
<td>Resveratrol</td>
<td>Arachis hypogaea, Pistacia vera</td>
<td>RAD51, Fatty acid synthase, ABCG2</td>
<td>HeLa SP cells, Breast, pancreatic</td>
<td>[17, 106-107]</td>
</tr>
<tr>
<td>Koenimarin</td>
<td>Murrayakoenimarin(L)</td>
<td>Caspase expression</td>
<td>Prostate, Breast</td>
<td>[108-109]</td>
</tr>
<tr>
<td>Curcinin</td>
<td>Curcuma longa</td>
<td>CD44 and EpCam markers</td>
<td>Breast, Colon, Glioma, Pancreatic</td>
<td>[17, 110-113]</td>
</tr>
<tr>
<td>Lovastatin</td>
<td>Pleurutus ostreatus, Camellia sinensis</td>
<td>CD44, SOX2, c-Myc, CBFβ and snail</td>
<td>Nasopharyngeal carcinoma</td>
<td>[17, 114]</td>
</tr>
<tr>
<td>Pomiferin</td>
<td>Mucuraupomiera</td>
<td>BM11, Nestin, and Nanog</td>
<td>Glioma</td>
<td>[116]</td>
</tr>
<tr>
<td>Beta-ionic acid</td>
<td>Walsura pinnata</td>
<td>Bcl-2 family, Survivin</td>
<td>Leukemia</td>
<td>[117]</td>
</tr>
<tr>
<td>Prodigiosin</td>
<td>Serratia marcescens</td>
<td>Survivin</td>
<td>Colon</td>
<td>[118]</td>
</tr>
<tr>
<td>Epigallocaethechingallate</td>
<td>Camellia sinensis</td>
<td>Nanog, EMT, XIAP, Bcl2, survivin</td>
<td>Prostate</td>
<td>[119]</td>
</tr>
<tr>
<td>BRM270 (extract)</td>
<td>Medicinal plant</td>
<td>CD44 &amp; nestin, cytokleitos, miRNA128</td>
<td>Glioblastoma, Adenocarcinoma</td>
<td>[120-121]</td>
</tr>
<tr>
<td>Berberine</td>
<td>Coptis Chinensis</td>
<td>LDL receptor mRNA expression</td>
<td>-</td>
<td>[17, 122]</td>
</tr>
</tbody>
</table>

Note: EGFR: Epidermal growth factor receptor; GRP78: Glucose-regulated protein 78; MMP-9: Matrix metalloproteinase 9; SOX9: Sry-box transcription factors 9; ALDH: Aldehyde dehydrogenase; ABCG2: ATP binding cassette subfamily G member 2; CD44: Cluster of differentiation 44; EpCAM: Epithelial cell adhesion molecule; c-Myc: Avian myelocytomatosis virus oncogene cellular homolog; CBFβ: core binding factor β; BMI1: B cell-specific Moloney murine leukemia virus integration site 1; Bcl-2: B cell leukemia 2 protein; EMT: Epithelial mesenchymal transition; XIAP: X-linked inhibitor of apoptosis protein.

Matrix Metalloproteinase (MMP-9) facilitates the tumor invasion and metastasis [100]. Wogonin is isolated from the root of Scutellaria baicalensis, and inhibits the mobilization of Osteosarcoma CSC by downregulation of Matrix Metalloproteinase (MMP-9) [100]. In vitro assays such as Gelatin zymography and western blotting assay were used to determine MMP-9 activity in osteosarcoma CSCs [100]. It was noted that MMP-9 activity is decreased in comparison to that of control [100]. In addition, wogonin treatment induce reduced growth of sphere and inhibits the colony formation significantly in CD133+ CAL72 CSCs [100].

Catharanthine, one type of terpenoids produced by blister beetles readily, targets leukemia stem cells and progenitor cells in NOD/SCID mice model via inducing down-regulation of hepatic leukemia factor, SLUG, NFIL3 and c-myc, thereby inducing p53 and the mitochondrial caspase cascade, resulting in apoptosis [101].

Brassica genus contains a natural indole carbinol called glucobrassicin and hydrolytic product of glucobrassicin is indole 3 carbinol (I3C), which inhibits the proliferation of both breast cancer cell line and in vivo tumor xenograft. I3C mediates its action through targeting nucleostemin, a nucleolus residing GTPase, is a stem cell marker of breast carcinoma [102]. In proliferating cells, murine double mutant-2 interacts with p53 protein through a signaling cascade. As a result, p53 cannot trigger its apoptotic response. I3C treatment promotes the interaction of nucleostemin with murine double mutant 2, an inhibitor of the p53 tumor suppressor, thereby disrupting the murine double mutant 2 interaction with p53. In addition, I3C induced nucleostemin to sequester murine double mutant 2 in a nucleolus compartment, thereby freeing p53 to mediate its apoptotic activity [102]. In addition, Triptolide exhibits cytotoxic effects against breast cancer stem cells by induction of apoptosis [103].

It is evident that tumor microenvironment plays a critical role in regulating breast tumor progression and signaling between preadipocytes and breast cancer cells have been found to promote breast tumor formation and metastasis [104]. It was demonstrated that Shikonin, a natural antitumor compound isolated from Lithospermum erythrorhizon, can inhibit preadipocyte signaling, and thereby inhibit nearby ductal carcinoma in situ (DCIS) cells [104]. In addition, co-culture of Shikonin with exosome derived from preadipocyte revealed that Shikonin-treated preadipocytes secrete exosomes with high levels of miR-140, which can inhibit nearby DCIS cells by targeting SOX9 signaling [104]. SOX9, a transcription factor, promotes preadipocyte differentiation which is regulated by miR-140. In cancer cells miR-140 is frequently silenced whereas treatment with Shikonin increased the expression of miR-140, resulting in the expression of SOX 9 mRNA. Thus, Shikonin alters preadipocyte differentiation by SOX/miRNA-140 pathway [104].

β-escin, a natural compound isolated from Aesculus hippocastanum, is more efficient in the killing of Glioma-Initiating Cells (GIC) by activating caspase dependent cell death when compared to that of currently used cytotoxic agents such as temozolomide, etoposide, and cisplatin [105]. Moreover, β-escin inhibits the expression of stemness markers (ALDH, SOX2, nestin) in both mesenchymal and neural glioma-initiating cells [105].

RAD51, a recombinase involved in DNA repair mechanism, and its upregulation in CSCs of cervical cancer cell line is associated with the insensitivity to etoposide [106]. Thus, targeting RAD51 still remains a promising aspect to eradicate CSCs. Resveratrol, a polyphenolic compound found abundantly in various herbs and fruits such as Arachis hypogaea, Pistacia vera, induced S phase cycle arrest and apoptosis of HeLa SP cells (enriched in CSCs) via downregulation of RAD51 [106]. Decreased RAD51 protein level was noted in resveratrol-treated CSCs when compared to HeLa SP without treatment or treated with etoposide alone [106]. Interesting-
ly, the synergistic inhibitory effect of resveratrol with Etoposide was noted in HeLa SP cells [106]. In addition, resveratrol inhibits lipogenesis and cell survival of all breast cancer cell lines (MCF7, MDA-MB231, and MDA-MB231 LM) by suppressing the expression of Fatty Acid Synthase (FAS) and induces apoptosis by upregulation of pro-apoptotic genes DAPK2 and BNIP3 [107].

Koenenbin, a natural bioactive compound originated from *Murraya koenigii* (L.) Spreng, exhibited potent growth inhibitory activity against PC-3 derived prostate CSCs and MCF7 breast CSCs [108, 109]. It was noted that koeninbin treatment caused G0/G1 and G2/M cell cycle arrest of ALDH-positive CSCs and induced apoptosis by activating Bax and caspase expression. In addition, koeninbin caused reduced expression of Bcl-2 and HSP70 when compared to that of control cells [108, 109].

Curcumin, an active polyphenolic curcuminoid found in *Curcuma longa* has been traditionally used to treat many cancer types [110-112]. It has the potential to eliminate CSCs in various cancers including, breast, colon, and gliomas [110-112]. Recently, it has been reported that curcumin has an anti-CSC role against gemcitabine-resistant pancreatic CSCs [113].

Nasopharyngeal carcinoma cells (5-8F and 6-10B) expressing higher stemness markers (CD44, SOX2, c-Myc, core binding factor β, and snail) undergo apoptotic death and exhibit reduced sphere forming capacity in the presence of a naturally occurring lipophilic statin Lovastatin (found in *Pleurotus ostreatus*, *Camellia sinensis*) [114]. Moreover, lovastatin treated induced 5-8F and 6-10B cells to arrest G2/M cell cycle phase, thereby stopping cell proliferation by blocking entrance into mitosis [114]. It also sensitizes nasopharyngeal carcinoma cells CSCs to CPA, a chemotherapeutic drug, is used to treat nasopharyngeal carcinoma cells [114].

Glioblastoma Multiforme (GBM), the most common and biologically aggressive form of a brain tumor in adults, is resistant to conventional chemo-radiotherapy [115]. The average survival rate of GBM patient is only 12-14 months after diagnosis [115]. Glioma Stem Cells (GSCs) are associated with tumor recurrence and diffuse infiltration, which aggravate the outcome of the disease [115]. Therefore, identification of compounds with the potentiality to target GSC could open new opportunity to manage this deadly disease. It was noted that Pomiferin extracted from the fruit of the *Maclura pomifera*, can inhibit glioma stem cell growth, invasion and sphere formation [116]. Pomiferin induced down-regulation of stemness-associated genes *i.e.* BMI1, Nestin, and Nanog around 2.5-fold in GSC and thereby can be used as therapeutic agents to inhibit the growth of glioma stem cells by regulating stemness-associated genes [116].

Betulonic Acid (BA), a pentacyclic lupane-type triterpenoid, is abundantly distributed in parts of many plant species [117]. BA isolated from the bark of *Walsura pinnata* exhibited intrinsic apoptotic activity against Leukemia Stem Cells (LSC) [117]. In addition, it reduced the viability and colony formation of LSC in a dose-dependent manner [117]. BA triggers apoptosis in LSC by increasing expression of apoptotic protein BAX while significantly reduces anti-apoptotic Bel-2 and survivin expression [117]. Furthermore, BA increased caspase 3, caspase 7 and caspase 9 activity in LSC with the loss of mitochondrial transmembrane potential. Moreover, BA induces apoptosis in LSC xenografted zebrafish through a mitochondrial pathway [117].

Induction of apoptosis is considered as an effective mechanism to eradicate CSCs and prodigiosin (2-methyl-3-pentyl-6-methoxyprodigiosene) induced apoptosis of colorectal cancer stem cells (isolated from HCT-116 cells) [118]. Prodigiosin is a secondary metabolite of *Serratia marcescens* that can effectively reduce cell viability, proliferation via reducing survivin expression with the concomitant increment of tumor suppressor miR-16-1 expression in colorectal CSC. It also induces the activation of caspase 3, thereby promoting apoptotic death of CSCs [118].

**Epigallocatechin** Gallate (EGCG) reduced the viability of CD44+ and CD133+ prostate CSCs originated from PC-3 and LNCaP cell lines [119]. Furthermore, EGCG inhibited sphere forming ability of CSCs in a dose-dependent manner [119]. Interestingly, it was noted that EGCG exhibits synergistic anti-CSC activity with quercetin against prostate CSCs [119]. EGCG induces apoptosis and growth inhibition by down-regulation of Nanog, EMT, XIAP, Bel-2 and survivin. It induces apoptosis through up-regulation of caspase-3/7 [119].

BRM270 is a natural compound exhibiting promising anticancer activity against many cancer types including glioblastoma, adenocarcinoma [120, 121]. For example, BRM270 induces apoptosis in MD13 glioblastoma stem cells by activating caspase-3 mediated cascade [120]. BRM270 treatment causes MD13 GSCs accumulation at G0/G1 and then induces apoptotic cell death [120]. In addition, BRM270 inhibits stemness properties of GSCs by decreasing the expression level of CD44 and nestin [120]. It also inhibits the tumour-sphere-forming capacity of MD13 GSCs [120]. Additionally, it suppresses in vivo tumor growth and cancer recurrence as well as sensitizes GSC to CCRT-a standard therapy for GBM patients [120]. Furthermore, BRM270 halts the CSC maintenance in adenocarcinoma (A549) cells by upregulation of miRNA-128 [120]. Reduced expression of miR-128 is correlated with the therapy-resistant property of cancer stem cells isolated from A549 cells [120]. However, treatment with BRM270 increased the expression of miR-128 by 2-3 folds, resulting in diminishing the chemoresistant property of A549 cells [121]. Hence, different natural compound inhibits the growth of CSCs in various cancer types [120-122]. Each of them has a promising role in diminishing the proliferative effect of CSCs. It should be an outstanding perspective to design novel anticancer drugs using them in clinical trials. Moreover, it is important to investigate a new multidimensional therapeutic approach starting from cyto-reduce of the disease plus epigenetic therapy with Stem Cell Differentiation Stage Factors (SCDSFs) [123]. In addition, in case of advanced level of disease, immunotherapy can be used to treat the cancer presenting phenotype in association with chemomodulation plus ablative therapies [123]. Therefore, SCDSFs could be utilized with current cancer stem cell therapies to regulate cancer stem cells more effectively.

**CONCLUSION AND FUTURE PERSPECTIVES**

Advancing in the understanding of cancer initiation and maintenance by CSCs reveals that this sup-population of cells is the main culprit of cancer treatment failure because of their multiple survival mechanisms. Despite the emergence of some promising treatment options targeting normal cancer cells, lack of unique, ubiquitous and single molecular targets that affect CSCs, are becoming the major concerns of cancer therapy. In the light of this, we have attempted to make a review of natural compounds having a wide range of anti-CSC activities. However, most of the compounds have been tested *in vitro*. Thus, the question remains, whether they are equally effective *in vivo* without adverse effects? To answer this question further research is needed. Previous findings suggest several anti-cancer drugs of natural origin and it is well established that drugs from natural origin are less toxic than their synthetic counterparts. Therefore, natural compounds with various anti-CSC activities may have the potential to act as a source of effective chemotherapeutic solution against CSCs with no or less side effects. Interestingly, some of them exert their activity in combination with currently available chemotherapeutic agents. Thus, it opens up the opportunity that these natural compounds can be used either individually or combined with available anticancer drugs. Therefore, further research is needed to engineer robust formula-
tions of drug or natural analogs that could effectively target CSCs without posing recognizable side effects to the patients.

AVAILABILITY OF DATA AND MATERIALS:

Not applicable

CONSENT FOR PUBLICATION

The work has not been previously published or being considered elsewhere and all the authors have contributed and agreed on the manuscript.

FUNDING

None.

CONFLICT OF INTEREST

None.

ACKNOWLEDGEMENTS

The University of Rajshahi, Rajshahi, Bangladesh is acknowledged for giving the technical support.

REFERENCES


Cancer Stem Cells and Natural Compound


Anti-Cancer Agents in Medicinal Chemistry, 2019, Vol. 19, No. 0

Das et al.


